The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,807.00
Bid: 1,806.50
Ask: 1,807.00
Change: -3.00 (-0.17%)
Spread: 0.50 (0.028%)
Open: 1,811.00
High: 1,814.50
Low: 1,806.50
Prev. Close: 1,810.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE: Glaxo joins Alector on brain treatment trials; backs leader

Fri, 02nd Jul 2021 14:32

(Alliance News) - GlaxoSmithKline PLC on Friday said it has partnered with Alector Inc to develop brain disease treatments, as it defends its leadership in response to a scathing open letter from activist investor Elliott Management Corp.

The pharmaceutical company said California-based immuno-neurology researchers Alector will receive USD700 million in upfront payments and up to USD1.5 billion in milestone payments, profit sharing and royalties as the pair unite to develop and trial neurodegenerative disease treatments.

Neurodegenerative diseases - such as dementia, Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease - affect brain function and are currently considered incurable.

GSK and Alector will co-develop progranulin-elevating monoclonal antibodies, designated AL001 and AL101, to treat a range of brain diseases.

The antibodies are designed to increase the level of the immune regulator known as progranulin, which has genetic links to multiple neurodegenerative disorders.

The company noted, Alector will initially lead both antibodies through phase 2 "proof-of-concept" trials, with the pair then sharing development responsibilities for late-stage studies. The companies will share all profits and losses from any commercialisation of the treatment.

GSK added, the AL001 antibody is also currently in a phase 2 study in symptomatic frontotemporal dementia patients, with a phase 2 development for amyotrophic lateral sclerosis planned for the second half of 2021.

Meanwhile, according to GSK, enrolment has already begun for a phase 3 trial of the AL001 antibody for candidates with, or at risk for, frontotemporal dementia due to a progranulin gene mutation.

No treatments are currently approved for frontotemporal dementia, which is a particularly severe and rapid acting form of the disease that most often effects under 65's. The disease affects between 50,000 and 60,000 people in the US and around 110,000 in the European Union.

Also on Friday, GSK defended Chief Executive Emma Walmsley as the right leader for the core pharmaceutical and vaccines business - even after the consumer division gets spun off - after coming under fire from activist investor Elliott Management.

The investor said it supported GSK's consumer healthcare spinoff, called New GSK, which includes toothpaste and over-the-counter medicines, from its pharmaceuticals and vaccines business.

However, without naming Walmsley, Elliott called for pharmaceutical and scientific experts to pick the "right leadership" for New GSK from internal and external candidates after years of underperformance.

"Despite the strengths of its people, its vaccines and its drugs, GSK has a poor record of execution and value creation. These shortcomings are clearly demonstrated in GSK's share price, which has underperformed every single peer over nearly every conceivable timeframe," Elliott said.

Walmsley's background is in consumer business, and she spent 17 years at L'Oreal SA before leading GSK's consumer business and then being promoted to group CEO in 2017.

On Friday, GSK said its largest shareholders support its strategy and have confidence in its leadership.

"The board strongly believes Emma Walmsley is the right leader of New GSK and fully supports the actions being taken by her and the management team, all of whom are subject to rigorous assessments of performance," GSK said in response to Elliot's letter.

GSK said it has been preparing for two new, appropriately qualified, independent boards ahead of the separation and that it has almost completed a six-month search for a chief executive officer for the consumer health business.

Shares in GlaxoSmithKline were trading marginally higher at 1,438.40 pence each in London on Friday afternoon.

By Scarlett Butler and Ivan Edwards; scarlettbutler@alliancenews.com; ivanedwards@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more
20 Feb 2024 15:10

PRESS: AJ Bell founder to join Applied Nutrition ahead of IPO - Sky

(Alliance News) - Supplements maker Applied Nutrition, plotting a London stock market float, is to add AJ Bell PLC founder Andy Bell as its chair, Sky News reported on Tuesday.

Read more
20 Feb 2024 08:55

IN BRIEF: Diageo welcomes GSK's CFO as non-executive director

Diageo PLC - London-based brewer and distiller sells more than 200 drinks brands, including Guinness stout, Captain Morgan rum and Johnnie Walker whisky - Appoints GSK PLC's chief financial officer and executive director, Julie Brown, as a non-executive director. Says she will succeed Alan Stewart as chair of the audit committee after his retirement following the firm's annual general meeting in September. Chair Javier Ferran says: "Julie brings many years of experience in financial, commercial and strategic roles in international companies operating in highly regulated industries. She is strongly committed to enabling diversity in business and to creating sustainable, long-term value for stakeholders. I look forward to her contribution to Board discussions and to working with her in progressing Diageo's ambition to be one of the most trusted and respected consumer products companies in the world."

Read more
15 Feb 2024 14:44

UK dividends calendar - next 7 days

Friday 16 February 
JPMorgan Asia Growth & Income PLCdividend payment date
JPMorgan Japan Small Cap Growth & Income PLCdividend payment date
Murray International Trust PLCdividend payment date
Premier Miton Group PLCdividend payment date
Schroder Oriental Income Funddividend payment date
Solid State PLCdividend payment date
Monday 19 February 
no events scheduled 
Tuesday 20 February 
Invesco Bond Income Plus Ltd 
Wednesday 21 February 
no events scheduled 
Thursday 22 February 
abrdn Asia Focus PLCex-dividend payment date
Alumasc Group PLCex-dividend payment date
AstraZeneca PLCex-dividend payment date
BlackRock Throgmorton Trust PLCex-dividend payment date
Braemar PLCex-dividend payment date
easyJet PLCex-dividend payment date
Ecofin US Renewables Infrastructure Trust PLCex-dividend payment date
Endeavour Mining PLCex-dividend payment date
FRP Advisory Group PLCex-dividend payment date
Gateley Holdings PLCex-dividend payment date
GSK PLCex-dividend payment date
Hercules Site Services PLCex-dividend payment date
Jersey Electricity PLCex-dividend payment date
Land Securities Group PLCex-dividend payment date
Molten Ventures VCT PLCex-dividend payment date
Northern Bear PLCex-dividend payment date
Redrow PLCex-dividend payment date
Samuel Heath & Sons PLCex-dividend payment date
Titon Holdings PLCex-dividend payment date
Unilever PLCex-dividend payment date
Van Elle Holdings PLCex-dividend payment date
Virgin Money UK PLCex-dividend payment date
Witan Investment Trust PLCex-dividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
15 Feb 2024 11:02

Berenberg hikes target price on GSK

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker GSK from £16.50 to £18.20 on Thursday, stating the group was moving closer to offsetting losses associated with the expiry of its patent on HIV drug dolutegravir.

Read more
15 Feb 2024 09:45

LONDON BROKER RATINGS: Jefferies cuts Kingfisher but Citi raises

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
15 Feb 2024 08:49

GSK completes USD1.4 billion purchase of respiratory firm Aiolos Bio

(Alliance News) - GSK PLC on Thursday said it has completed the acquisition of Aiolos Bio Ltd, expanding its respiratory portfolio with a potential "best-in-class" asthma treatment.

Read more
13 Feb 2024 16:53

LONDON MARKET CLOSE: Stocks in red amid sticky US inflation data

(Alliance News) - Stock prices in London closed in the red on Tuesday, after a key US inflation reading came in hotter-than-expected.

Read more
13 Feb 2024 16:21

London close: Stocks fall as US inflation tops expectations

(Sharecast News) - London markets ended the trading day in negative territory on Tuesday, influenced by concerns over higher inflation figures from the United States and a deceleration in wage growth within the UK.

Read more
13 Feb 2024 16:21

London close: Stocks fall as US inflation tops expectations

(Sharecast News) - London markets ended the trading day in negative territory on Tuesday, influenced by concerns over higher inflation figures from the United States and a deceleration in wage growth within the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.